Literature DB >> 21244762

Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders.

L Cantarini1, O M Lucherini, F Iacoponi, R Cimaz, G Simonini, D Rigante, F Laghi Pasini, C T Baldari, P L Capecchi, M G Brizi, M Galeazzi.   

Abstract

To date, the rate of detection of autoinflammatory gene mutations in patients suspected of having an autoinflammatory disorder is very low. However, most of these data refer to pediatric populations. The relative rarity and lack of information on adult-onset autoinflammatory diseases make it likely that mutations will be found in an even smaller percentage of cases. Our aim was to develop and validate a set of variables for predicting the risk that a given adult patient presenting with recurrent fever episodes carries mutations in the MEFV or TNFRSF1A genes, in order to increase the probability of obtaining positive results on genetic testing. One hundred and ten consecutive patients with a clinical history of periodic fever attacks were screened for mutations in the TNFRSF1A and the MEFV genes. The mean age at disease onset was 27.85 years. Detailed information about each patient?s family history, personal history, and clinical manifestations were retrospectively collected. A diagnostic score was constructed based on univariate and multivariate analysis in a randomly-selected dataset (training set; n=40). The score was validated on an independent set of the remaining patients (validation set; n=70). Age at onset (odds ratio 0.958, P =0.050), positive family history of recurrent fever episodes (OR 5.738, P = 0.006 ), thoracic pain (OR 7.390, P = 0.002), abdominal pain (OR 2.853, P = 0.038) and skin involvement (OR 8.241, P = 0.003) were independently correlated with a positive genetic test result. A diagnostic score was calculated using the linear combination of the estimated coefficients of the logistic model (cut off equal to 0.24) revealing high sensitivity (0.94), high specificity (0.94) and high accuracy (0.94). We have identified variables that appear to be strongly related to the probability of detecting gene mutations in MEF and TNFRSF1A in adults, thus improving the evaluation of patients with suspected autoinflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21244762     DOI: 10.1177/039463201002300417

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  15 in total

Review 1.  Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective.

Authors:  Donato Rigante; Antonio Vitale; Marco Francesco Natale; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-12-03       Impact factor: 2.980

2.  The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Anna De Palma; Ida Orlando; Stefano Gentileschi; Jurgen Sota; Antonella Simpatico; Claudia Fabiani; Mauro Galeazzi; Bruno Frediani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 3.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

Review 4.  The protean ocular involvement in monogenic autoinflammatory diseases: state of the art.

Authors:  Vittoria Bascherini; Carmela Granato; Giuseppe Lopalco; Giacomo Emmi; Lorenzo Vannozzi; Daniela Bacherini; Rossella Franceschini; Florenzo Iannone; Annabella Salerni; Francesco Molinaro; Mario Messina; Bruno Frediani; Carlo Selmi; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-04-02       Impact factor: 2.980

Review 5.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

Review 6.  Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.

Authors:  Marco Cattalini; Martina Soliani; Giuseppe Lopalco; Donato Rigante; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2016-05-25       Impact factor: 3.397

Review 7.  Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis.

Authors:  Luca Cantarini; Massimo Imazio; Maria Giuseppina Brizi; Orso Maria Lucherini; Antonio Brucato; Rolando Cimaz; Mauro Galeazzi
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 10.817

Review 8.  Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Francesco Caso; Isabella Muscari; Flora Magnotti; Maria Giuseppina Brizi; Susanna Guerrini; Maria Patti; Leonardo Punzi; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

9.  Caution Should be Used in the Recognition of Adult-Onset Autoinflammatory Disorders: Facts or Fiction?

Authors:  Luca Cantarini; Orso Maria Lucherini; Donato Rigante
Journal:  Front Immunol       Date:  2013-04-23       Impact factor: 7.561

Review 10.  Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease.

Authors:  Francesco Caso; Paola Galozzi; Luisa Costa; Paolo Sfriso; Luca Cantarini; Leonardo Punzi
Journal:  RMD Open       Date:  2015-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.